Study of DF9001 in Patients With Advanced Solid Tumors

NCT05597839 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: DF9001
DRUG: KEYTRUDA® (pembrolizumab)

Sponsor

Dragonfly Therapeutics

Collaborators

[object Object]